NCT06621329 Transnasal Sphenopalatine Ganglion Block for Treatment of Acute Subarachnoid Hemorrhage Associated Headache
| NCT ID | NCT06621329 |
| Status | Recruiting |
| Phase | Phase 2, Phase 3 |
| Sponsor | University of California, Davis |
| Condition | SAH (Subarachnoid Hemorrhage) |
| Study Type | INTERVENTIONAL |
| Enrollment | 40 participants |
| Start Date | 2024-10-17 |
| Primary Completion | 2026-07 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 40 participants in total. It began in 2024-10-17 with a primary completion date of 2026-07.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The study titled \"Transnasal sphenopalatine ganglion block for treatment of acute subarachnoid hemorrhage associated headache\" is a randomized controlled pilot study aimed at evaluating the efficacy of a transnasal sphenopalatine ganglion (SPG) block in addition to standard pain medication for reducing headache severity in patients with acute subarachnoid hemorrhage (aSAH). The study also examines whether this intervention can reduce opioid requirements during hospitalization and upon discharge.
Eligibility Criteria
Inclusion Criteria: * Acute subarachnoid hemorrhage * Age greater than 18 years * Secured aneurysm * Patient can verbalize pain score to clinician, nurse, medical translator, or surrogate decision * maker * Patient or surrogate decision maker is available to consent Exclusion Criteria: * Less than 18 years old * Unsecured aneurysm * Pregnant or lactating * Prisoner * Unable to verbalize pain score to clinician, nurse, medical translator, or surrogate decision maker * Nasal or facial trauma or surgery within the last three months * Allergy to lidocaine, bupivacaine, or dexamethasone * Patient is unable to consent and no available surrogate decision maker
Contact & Investigator
Christine Picinich, MS, AGACNP-BC, CCRN
PRINCIPAL INVESTIGATOR
University of California, Davis
Frequently Asked Questions
Who can join the NCT06621329 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 100 Years, studying SAH (Subarachnoid Hemorrhage). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06621329 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT06621329 currently recruiting?
Yes, NCT06621329 is actively recruiting participants. Contact the research team at jfwang@ucdavis.edu for enrollment information.
Where is the NCT06621329 trial being conducted?
This trial is being conducted at Sacramento, United States.
Who is sponsoring the NCT06621329 clinical trial?
NCT06621329 is sponsored by University of California, Davis. The principal investigator is Christine Picinich, MS, AGACNP-BC, CCRN at University of California, Davis. The trial plans to enroll 40 participants.